Time: 3:44

AusBiotech

Sinodinos announces intention for women’s advisory roundtable

The newly-appointed Minister for Industry, Innovation and Science, Senator Arthur Sinodinos, has announced an intention to establish a women’s advisory to guide policy in the innovation sector. Addressing the Women in Venture Capital Forum last week in Sydney, the Minister said he wanted his stewardship of the portfolio to be marked by an Australia-wide adoption of … Continue reading Sinodinos announces intention for women’s advisory roundtable

Uncertainty on R&D Tax Incentive causing harm

Constant reviews and recent changes to the Research and Development (R&D) Tax Incentive are jeopardising Australian innovation and prompting Australian biotechnology firms to reconsider their R&D investment strategy, says the McKell Institute. In a recent report, Committing to the Innovation Nation: Why the R&D Tax Incentive is so important for Australia, the McKell Institute examined … Continue reading Uncertainty on R&D Tax Incentive causing harm

AusBiotech suggests FSANZ amend cost recovery plan

AusBiotech has responded to Food Standards Australia New Zealand (FSANZ) call for comment on the draft Cost Recovery Implementation Statement (dCRIS), rejecting the proposed model to recover from industry direct and indirect costs of all FSANZ staff, and the total cost of the FSANZ Board, which are not directly involved in the specific activity in … Continue reading AusBiotech suggests FSANZ amend cost recovery plan

Australian life science companies to engage with Asian investors

Emerging life science companies are encouraged to take advantage of Asia’s propitious investment landscape and join AusBiotech’s Asian Investment Series. The Series will be held in three key Asian investment hubs during March, and is expected to draw more than 200 qualified investors to each event. Australia’s flourishing life sciences sector, national focus on innovation … Continue reading Australian life science companies to engage with Asian investors

TGA Bill to cut ‘red tape’ stalls for Inquiry

The passage of a legislative bill to enable regulatory reform measures stemming from the review of Medicines and Medical Devices Regulation (MMDR) was last week delayed with its referral for Inquiry. The Senate has referred the Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 to the Senate Community Affairs Legislation Committee for inquiry and report. The … Continue reading TGA Bill to cut ‘red tape’ stalls for Inquiry

Last call for abstracts for international research conference on mechanics in medicine and biology

The International Conference on Mechanics in Medicine and Biology (ICMMB) scientific program committee has made its final call for abstracts, inviting submissions by Friday 17 February 2017. This year AusMedtech 2017 & ICMMB 2017 will be co-presented in Melbourne, 24 – 25 May. Abstracts that present mechanics, medicine, biology and its related fields are expected … Continue reading Last call for abstracts for international research conference on mechanics in medicine and biology

AusBiotech to initiate clinical trials advisory group

AusBiotech is inviting members to express interest in joining a new advisory group to provide guidance and advice on policy impacting clinical trials (CTs). During 2016, more than 80 AusBiotech members attended invitation-only roundtables to discuss issues related to CTs, in a series of consultation meetings, held across Australia. Roundtable consultations were held in Queensland, … Continue reading AusBiotech to initiate clinical trials advisory group

AusBiotech consults biotech CEOs on industry advocacy

AusBiotech has launched its annual consultation of membership issues, calling for leaders of biotechnology companies to respond to the annual CEO Biotechnology Industry Position Survey 2017, as a matter of importance. AusBiotech conducts the confidential survey and holds supporting roundtables in each state early each year, to seek formally, opinions and information from the leaders … Continue reading AusBiotech consults biotech CEOs on industry advocacy